Can Intranasal Nalmefene Reduce the Number of Opioid Overdose Deaths?
| Errataetall: |
CommentOn: Clin Pharmacol Drug Dev. 2024 Jan;13(1):58-69. - PMID 37496452 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Clinical pharmacology in drug development - 13(2024), 3 vom: 18. März, Seite 315-316 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sellers, Edward M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5S6W795CQM |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 16.04.2024 published: Print-Electronic CommentOn: Clin Pharmacol Drug Dev. 2024 Jan;13(1):58-69. - PMID 37496452 Citation Status MEDLINE |
|---|
| doi: |
10.1002/cpdd.1381 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367795248 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367795248 | ||
| 003 | DE-627 | ||
| 005 | 20240417232432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cpdd.1381 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM367795248 | ||
| 035 | |a (NLM)38289185 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sellers, Edward M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Can Intranasal Nalmefene Reduce the Number of Opioid Overdose Deaths? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Clin Pharmacol Drug Dev. 2024 Jan;13(1):58-69. - PMID 37496452 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a nalmefene |2 NLM | |
| 650 | 7 | |a TOV02TDP9I |2 NLM | |
| 650 | 7 | |a Naltrexone |2 NLM | |
| 650 | 7 | |a 5S6W795CQM |2 NLM | |
| 650 | 7 | |a Narcotic Antagonists |2 NLM | |
| 700 | 1 | |a Romach, Myroslava K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology in drug development |d 2012 |g 13(2024), 3 vom: 18. März, Seite 315-316 |w (DE-627)NLM250185032 |x 2160-7648 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:3 |g day:18 |g month:03 |g pages:315-316 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cpdd.1381 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 3 |b 18 |c 03 |h 315-316 | ||